Cadence plans to try again for FDA approval of Ofirmev

04/19/2010 | Bloomberg Businessweek

Cadence Pharmaceuticals plans to resubmit its pain and fever medicine Ofirmev for FDA approval within the next 30 days. In a meeting with the agency and a third-party manufacturer, the drugmaker said the agency did not request additional data on the drug, an injectable version of acetaminophen that was rejected by the FDA in February because of manufacturing concerns.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide